Literature DB >> 30266338

Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo.

Changjie Lv1, Wenkai Liu1, Bin Wang1, Ruyi Dang1, Li Qiu1, Juan Ren1, Chuanqi Yan1, Zengqi Yang2, Xinglong Wang3.   

Abstract

Pseudorabies virus (PRV) is an important viral pathogen of pigs that causes huge losses in pig herds worldwide. Ivermectin is a specific inhibitor of importin-α/β-dependent nuclear transport and shows antiviral potential against several RNA viruses by blocking the nuclear localization of viral proteins. Since the replication of DNA viruses is in the nucleus, ivermectin may be functional against DNA virus infections if the DNA polymerase or other important viral proteins enter the nucleus via the importin-α/β-mediated pathway. Here, we determined whether ivermectin suppresses PRV replication in hamster kidney BHK-21 cells and investigated the effect of ivermectin on the subcellular localization of the PRV UL42 protein, the accessory subunit of PRV DNA polymerase. Also, an in vivo anti-PRV assay was conducted in mice. Our data demonstrate that ivermectin treatment inhibits PRV infection in cells in a dose-dependent manner. Treatment of PRV-infected cells with ivermectin significantly suppressed viral DNA synthesis and progeny virus production. Ivermectin disrupted the nuclear localization of UL42 by targeting the nuclear localization signal of the protein in transfected cells. Ivermectin treatment increased the survival rates of mice infected with PRV and relieved infection as indicated by lower clinical scores and fewer gross lesions in the brain. Together, our results suggest that ivermectin may be a therapeutic or preventative agent against PRV infection.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral; DNA polymerase; Ivermectin; Nuclear import; Pseudorabies virus

Mesh:

Substances:

Year:  2018        PMID: 30266338     DOI: 10.1016/j.antiviral.2018.09.010

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  33 in total

1.  Inhibition of Human Adenovirus Replication by the Importin α/β1 Nuclear Import Inhibitor Ivermectin.

Authors:  Cason R King; Tanner M Tessier; Mackenzie J Dodge; Jason B Weinberg; Joe S Mymryk
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 2.  A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.

Authors:  Robert T Kinobe; Leigh Owens
Journal:  Fundam Clin Pharmacol       Date:  2021-01-28       Impact factor: 2.748

Review 3.  A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.

Authors:  Priyanka Dash; Subhashree Mohapatra; Sayantan Ghosh; Bismita Nayak
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

4.  Potential therapeutic effects of Ivermectin in COVID-19.

Authors:  Nastaran Barati; Seyedmousa Motavallihaghi; Banafsheh Nikfar; Shahla Chaichian; Amir Abbas Momtazi-Borojeni
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-10

Review 5.  Ivermectin: An Anthelmintic, an Insecticide, and Much More.

Authors:  Richard J Martin; Alan P Robertson; Shivani Choudhary
Journal:  Trends Parasitol       Date:  2020-11-11

Review 6.  An update on emerging therapeutics to combat COVID-19.

Authors:  Naveed Nazir Shah; Showkat Ul Nabi; Muzafar Ahmad Rather; Qudratullah Kalwar; Sofi Imtiyaz Ali; Wajid Mohammad Sheikh; Alveena Ganai; Showkeen Muzamil Bashir
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-06-11       Impact factor: 3.688

Review 7.  Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.

Authors:  Zhihong Zuo; Ting Wu; Liangyu Pan; Chenzhe Zuo; Yingchuo Hu; Xuan Luo; Liping Jiang; Zanxian Xia; Xiaojuan Xiao; Jing Liu; Mao Ye; Meichun Deng
Journal:  Front Pharmacol       Date:  2021-02-08       Impact factor: 5.810

8.  Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.

Authors:  Khan Sharun; Kuldeep Dhama; Shailesh Kumar Patel; Mamta Pathak; Ruchi Tiwari; Bhoj Raj Singh; Ranjit Sah; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales; Hakan Leblebicioglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-05-30       Impact factor: 3.944

9.  What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results.

Authors:  Vanessa Aparecida Marcolino; Tatiana Colombo Pimentel; Carlos Eduardo Barão
Journal:  Eur J Pharmacol       Date:  2020-08-08       Impact factor: 4.432

10.  Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.

Authors:  Fatemeh Heidary; Reza Gharebaghi
Journal:  J Antibiot (Tokyo)       Date:  2020-06-12       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.